Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 6/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108345 | 0.93 | PPARD (0.41) | PPARDDDR1CNR1CNR2MALT1 | |
| SCHEMBL3113330 | 0.92 | DDR1 (0.41) | PPARDDDR1CNR1CNR2MALT1 | |
| SCHEMBL3100310 | 0.89 | EPHX2 (0.40) | PPARDDDR1CNR1CNR2GCGR | |
| SCHEMBL3100296 | 0.86 | DDR1 (0.45) | PPARDDDR1CNR1CNR2MALT1 | |
| SCHEMBL3711570 | 0.85 | MALT1 (0.36) | PPARDCNR1CNR2MALT1GCGR | |
| SCHEMBL3111104 | 0.85 | DDR1 (0.44) | PPARDDDR1CNR1CNR2MALT1 | |
| SCHEMBL3107244 | 0.83 | PPARD (0.44) | PPARDDDR1CNR1CNR2MALT1 | |
| SCHEMBL3110196 | 0.81 | DPP4 (0.48) | PPARDDDR1CNR1CNR2MALT1 | |
| SCHEMBL3114614 | 0.80 | DDR1 (0.44) | PPARDDDR1CNR1CNR2EPHX2 | |
| SCHEMBL3115892 | 0.80 | DDR1 (0.43) | PPARDDDR1CNR1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209768-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-28 | — | — | EP | claimed |
| WO-2009087285-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | claimed |
| US-8362045-B2 | 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ALK, ROS1, CYP11B2 | PPARD 1034/4885DDR1 1315/4885CNR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.